Literature DB >> 31391850

Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients.

Laith N Al-Eitan1,2, Doaa M Rababa'h1, Mansour A Alghamdi3, Rame H Khasawneh4.   

Abstract

Breast cancer pharmacogenetics is increasingly being explored due to chemotherapy resistance among certain classes of patients. The ATP binding cassette (ABC) transporter genes have been previously implicated in breast cancer progression and drug response. In the present study, single nucleotide polymorphisms (SNPs) from the ABCC1, ABCC2, ABCB1, and ABCG2 genes were screened in breast cancer patients and healthy volunteers from the Jordanian-Arab population. Only the ABCB1 SNPs showed a significant association with BC in Jordanian-Arab patients, and the ABCB1 SNP rs2032582 exhibited a strong genotypic association with BC. With regard to the clinical characteristics of BC, the ABCC2 SNPs rs2273697 and rs717620 were found to be significantly associated with age at breast cancer diagnosis and breastfeeding status, while the ABCB1 SNP rs1045642 was significantly associated with age at breast cancer diagnosis. In terms of pathological characteristics, the ABCC1 SNP rs35628 and the ABCB1 SNP rs2032582 were significantly associated with tumor size, the ABCC2 SNP rs2273697 was significantly associated with estrogen receptor status, and the ABCG2 SNP rs2231142 was significantly associated with axillary lymph node status. In this current study, we assume that significant genetic variants within the ABC superfamily may increase the risk of breast cancer among Jordanian women. Furthermore, these variants might be responsible for worse BC prognosis.

Entities:  

Year:  2019        PMID: 31391850      PMCID: PMC6662487          DOI: 10.1155/2019/6425708

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


1. Introduction

Breast cancer (BC) is the most common female malignancy in the majority of countries [1]. Arab populations suffer from lower but steadily rising BC incidence rates compared to their American and European counterparts, and the clinical characteristics of the disease also differ between the aforementioned populations [2]. Such population-level differences in BC predisposition have been attributed to genetics and have been widely investigated, with different mutations having different levels of association with BC [3]. Compounding this issue is the fact that Arab BC genetics are not well researched, and much less is known about the genes involved in BC progression and drug response in Arab patients [4]. The ATP binding cassette (ABC) transporters comprise seven subfamilies of membrane proteins that facilitate the transport and modulate the effects of a wide range of drugs and their metabolites [5, 6]. Remarkably, an overexpression of certain ABC transporters in cancer cell lines resulted in multidrug resistance (MDR) and a potential failure of chemotherapy [7, 8]. For example, the ABCC1 gene, also known as multidrug resistance-associated protein 1 (MRP1), is associated with worsened prognoses in a wide range of tumors, while the ABCC2 gene was found to contribute to drug resistance [9, 10]. Likewise, the ABCB1 gene is highly polymorphic and induces chemoresistance by preventing drug accumulation in cancer cells [7]. In addition, the ABCG2 gene, also known as the breast cancer resistance protein (BCRP), is responsible for the transport of many conventional chemotherapeutics and causes MDR in various cancer cells [11]. In the present study, four SNPs of ABC transporter genes, namely ABCC1, ABCC2, ABCB1, and ABCG2, were screened in Jordanian Arabs with and without breast cancer. Previous reports have indicated that these genes play a critical role in increasing tumor risk, especially in breast cancer [9, 11]. The aim of this study is to determine whether the aforementioned genes play a significant role in Jordanian breast cancer patients.

2. Materials and Methods

2.1. Ethical Approval and Conduct

The present study was given ethical approval by the Institutional Review Board (IRB) at Jordan University of Science and Technology. Written informed consent was obtained from all participants in this study before blood sample withdrawal.

2.2. Study Population and Design

The study cohort consisted of 222 women diagnosed with breast cancer as well as 218 healthy matched volunteers. All participants were recruited from the Jordanian population and were of Arab descent. 5 ml of blood were withdrawn from each participant into EDTA tubes and refrigerated until DNA extraction.

2.3. Genomic Extraction and Genotyping

Genomic DNA was extracted from a total of 440 blood samples using the Wizard® Genomic DNA Purification Kit (Promega, USA). Extracted DNA was evaluated in terms of concentration (ng/μl) and purity (A260/280) quantity using the Nano-Drop ND-1000 UV-Vis Spectrophotometer (BioDrop, UK). DNA samples were then loaded onto an agarose gel to confirm product quality. Samples that met our requirements were diluted using nuclease-free water for a final concentration of 20 ng/μl and a final volume of 30 μl. Genotyping was carried out by the Melbourne node of the Australian Genome Research Facility (AGRF) using the Sequenom MassARRAY® system (iPLEX GOLD) (Sequenom, San Diego, CA, USA).

2.4. Denomination of Genotypic-Phenotypic Correlation

In this study, several clinical and pathological features of BC were investigated in correlation with the studied variants. Clinical and pathological information for patients was collected from their medical records. P values were selected to estimate the association between SNPs and risk of BC. The analyses were done per genotype.

2.5. Statistical Analysis

Case-control analyses were carried out using different statistical software. Allelic and genotypic frequencies were calculated using the Hardy-Weinberg equilibrium (HWE) equation (Court lab - HW calculator) (http://www.oege.org/software/hwe-mr-calc.html). The Statistical Package for the Social Sciences (SPSS), version 25.0 (SPSS, Inc., Chicago, IL) was used to calculate the p values that allowed discrimination between cases and controls in association with the genotype. It also facilitated the analysis of the different genotype models. On the other hand, genotype-phenotype assessment was performed using the Chi-Square test and ANOVA tests [12]. P value denoted statistical significance if they were less than 0.05.

3. Results

3.1. ABC Transporter Variants and Their Minor Allele Frequencies (MAF)

Table 1 displays the SNPs of the ABCC1, ABCC2, ABCB1, and ABCG2 candidate genes. All of the polymorphic SNPs were tested for minor allele frequencies (MAF) and HWE p values in both the cases and controls (Table 1).
Table 1

Minor allele frequencies among breast cancer patients and healthy controls and the HWEc p value of ABC gene polymorphisms.

GeneSNP IDSNP position aCases (n = 222)Controls (n = 218)
MAbMAFcHWEdMAbMAFcHWEd
p-value
p-value
ABCC1rs3562616076758T0.380.3T0.410.12
rs3562816077249G0.10.049G0.110.27
rs414835116076711T0.160.037T0.2N/A

ABCC2rs227369799804058A0.25N/AA0.240.089
rs374006599845936G0.23N/AG0.210.066
rs71762099782821T0.120.75T0.130.38

ABCB1rs104564287509329T0.350.025T0.430.026
rs112850387550285A0.360.039A0.440.074
rs203258287531302T0.030.4591T0.010.615

ABCG2rs223114288131171T0.040.552T0.040.572

aChromosome positions are based on NCBI Human Genome Assembly Build. bMA: minor allele. cMAF: minor allele frequency. dHWE: Hardy–Weinberg equilibrium. N/A: not applicable.

3.2. Association between ABC Transporter SNPs and Breast Cancer (BC)

The allelic and genotypic frequencies of the ABC transporter SNPs were determined for both cases and controls (Table 2). All three ABCB1 SNPs were found to be significantly associated with BC in Jordanian patients, with rs1045642, rs1128503, and rs2032582 having p values of 0.01164587, 0.01610842, and 0.03565022, respectively. Figure 1 shows a representative scatter pattern for rs1045642 of ABCB1. In contrast, only the rs2032582 SNP of ABCB1 showed a strong genotypic association with BC (p value = 1e-8, OR =6.72, 95% CI = 4.27 to 10.57). rs2032582 is a triallelic polymorphism comprising the A, C, and T (minor) alleles (the homozygous TT variant was not estimated in the current study population). None of the other investigated SNPs showed any significant correlation with BC, as all the allelic and genotypic frequencies were greater than 0.05 (Table 2).
Table 2

Association of the investigated ABCC1, ABCC2, ABCB1, and ABCG2 SNPs and breast cancer (BC).

GeneSNP IDAllelic and Genotypic Frequencies in Cases and Controls
Allele/GenotypeCasesControls P-valueChi-square
(n = 222)(n = 218)
ABCC1 rs35626G283(0.65)256 (0.59)0.0733.214
T155 (0.35)180 (0.41)
GG95 (0.43)81(0.37)0.2163.063
GT93 (0.42)94(0.43)
TT31 (0.14)43 (0.2)
rs35628A394 (0.9)388 (0.89)0.7880.072
G44 (0.1)46 (0.11)
AA180(0.82)175(0.81)0.8200.395
AG34(0.16)38(0.18)
GG5(0.02)4(0.02)
rs4148351C369(0.84)346(0.8)0.0823.021
T69 (0.16)88 (0.2)
CC160 (0.73)138 (0.64)0.0685.374
CT49 (0.22)70(0.32)
TT10 (0.05)9(0.04)

ABCC2 rs2273697G332(0.75)331(0.76)0.7780.079
A108 (0.25)103 (0.24)
AA13 (0.06)17(0.08)0.4121.773
GA82 (0.37)69(0.32)
GG125 (0.57)131(0.6)
rs3740065A341(0.77)345(0.79)0.4780.503
G101(0.23)91(0.21)
AA131(0.59)141(0.65)0.2852.51
AG79(0.36)63(0.29)
GG11(0.0514(0.06)
s717620C387(0.88)377(0.87)0.2852.51
T55(0.12)57 (0.13)
CC170(0.77)165(0.76)0.9280.149
CT47(0.21)47(0.22)
TT4(0.02)5(0.02)

ABCB1 rs1045642C288(0.65)248(0.57)0.0126.364
T152(0.35)186(0.43)
CC102(0.46)79(0.36)0.0635.499
CT84(0.38)90(0.41)
TT34(0.15)48(0.22)
rs1128503A278(0.64)242(0.56) 0.016 5.791
G158(0.36)192(0.44)
AA36(0.17)49(0.23)0.0745.189
GA86(0.39)94(0.43)
GG96(0.44)74(0.34)
rs2032582A144(0.33)174(0.43) 0.035 6.668
C284(0.65)252(0.58)
T12(0.03)6(0.01)
AA29(0.13)41(0.19) 1e-8 44.386
CA82(0.37)90(0.42)
CC97(0.44)79(0.37)
TA49(0.02)2(0.0093)
TC8(0.04)4(0.02)

ABCG2 rs2231142T17(0.04)16(0.04)0.9020.015
G425 (0.96)418 (0.96)
GG204(0.92)201(0.93)0.8990.016
GT17(0.08)16(0.07)

P value <0.05 was considered as significant.

Figure 1

Scatter plot for rs1045642 within ABCB1 gene. Each Dot represents a sample while different genotypes are indicated with different colors.

Further genetic analyses were carried out to test for the association of different genetic models with BC. Table 3 summarizes three different genetic models and the chi-squared value for each. The ABCG2 gene was excluded from the analysis because it expressed only two genotypes. For the ABCC1 SNP rs4148351, Het (CT) versus Common Hz (CC) was found to be associated with BC in Jordanian Arabs (χ2 = 5.33; p value <0.05). Similarly, for the ABCB1 SNP rs1128503, the Rare Hz (AA) versus Common Hz (GG) model was related to BC in Jordanian Arabs (χ2 =4.52; p value <0.05). No such association was found for any of the ABCC2 SNPs (Table 3).
Table 3

Genetic association analysis for the ABCC1, ABCC2, ABCB1, and ABCG2 SNPs using different genetic models.

GeneSNP IDCategory TestOdds Ratio95% CIChi square
ABCC1 rs35626Het (GT) vs. Common Hz (GG)0.840.56-1.270.65
Rare Hz (TT) vs. Het (GT)0.730.42-1.251.31
Rare Hz (TT) vs. Common Hz (GG)0.610.36-1.063.04
rs35628Het (AG) vs. Common Hz (AA)0.870.52-1.440.29
Rare Hz (GG) vs. Het (AG)1.40.35-5.630.22
Rare Hz (GG) vs. Common Hz (AA)1.220.32-4.60.08
rs4148351Het (CT) vs. Common Hz (CC)0.60.39-0.935.33
Rare Hz (TT) vs. Het (AG)1.580.6-4.190.88
Rare Hz (TT) vs. Common Hz (CC)0.960.38-2.430.01

ABCC2 rs2273697Het (GA) vs. Common Hz (GG)1.550.71-3.421.21
Rare Hz (AA) vs. Het (GA)0.80.54-1.21.14
Rare Hz (AA) vs. Common Hz (GG)1.250.58-2.680.32
rs3740065Het (GA) vs. Common Hz (AA)1.350.9-2.032.08
Rare Hz (GG) vs. Het (GA)0.630.27-1.481.16
Rare Hz (GG) vs. Common Hz (AA)0.850.37-1.930.16
rs717620Het (CT) vs. Common Hz (CC)0.970.61-1.530.02
Rare Hz (TT) vs. Het (CT)0.80.2-3.170.1
Rare Hz (TT) vs. Common Hz (CC)0.780.2-2.940.14

ABCB1 rs1045642Het (CT) vs. Common Hz (CC)0.720.48-1.12.32
Rare Hz (TT) vs. Het (CT)0.850.5-1.430.39
Rare Hz (TT) vs. Common Hz (CC)0.610.37-1.033.46
rs1128503Het (GA) vs. Common Hz (AA)1.250.74-2.10.68
Rare Hz (GG) vs. Het (GA)1.420.93-2.162.65
Rare Hz (GG) vs. Common Hz (AA)1.771.04-2.994.52

∗ For significant association χ2 should be >3.84 with P<0.025.

CI indicates confidence interval.

3.3. Association between ABC Transporter SNPs and Major Prognostic Factors of Breast Cancer (BC)

Certain clinical and pathological characteristics of BC serve as major prognostic factors for the disease that are exploited in the process of treatment selection. None of the ABCC1 SNPs showed any significant association with the clinical characteristics of BC, but the ABCC2 SNPs rs2273697 and rs717620 were found to be significantly associated with age at breast cancer diagnosis (p value = 0.042) and breastfeeding status (p value = 0.05), respectively (Table 4). Meanwhile, the ABCC1 SNP rs35628 was associated with the pathological characteristic of tumor size (p value = 0.014), while the ABCC2 SNP rs2273697 was significantly associated with estrogen receptor status (p value = 0.013) (Table 4).
Table 4

Association between different ABCC1 and ABCC2 SNP genotypes and the clinicopathological characteristics of breast cancer (BC).

Clinical characteristics ABCC1 ABCC2
rs35626 GG vs GT vs TTrs35628 AA vs AG vs GGrs4148351 CC vs CT vs TTrs2273697 AA vs AG vs GGrs3740065 AA vs AG vs GGrs717620 CC vs CT vs TT
Body mass index ∗∗0.5350.1160.0680.8130.4610.084

Age at first pregnancy ∗∗0.9900.6240.3580.3810.9210.458

Age at BC diagnosis ∗∗0.3110.3520.1980.0420.1940.104

Allergy 0.8080.8240.8670.5010.3240.065

Age at menarche ∗∗0.2190.8240.3730.8200.7470.611

Breastfeeding status 0.2840.1170.7610.4390.3400.005

Age at menopause ∗∗0.4370.6650.3730.1150.1550.251

Family history 0.6690.6050.7620.4720.8910.415

Comorbidity 0.7640.9670.9760.1300.7410.140

Smoking 0.2370.2870.1630.3200.4060.362

Pathological characteristics

Progesterone receptor status 0.2920.5160.2440.6100.8230.423

Estrogen receptor status 0.7300.5500.5620.0130.8390.125

HER2 0.1460.5000.3300.4410.2260.842

IHC profile0.0130.8380.2600.3810.7750.270

Tumor differentiation 0.7540.9400.9630.7680.7180.431

Axillary lymph nodes 0.1130.1840.8170.1380.9890.213

Tumor stage 0.4910.7510.6650.7480.9990.357

Histology classification 0.9630.5020.3480.3010.2940.661

Tumor size ∗∗0.8880.0140.9680.7200.5760.922

Lymph node involvement 0.6940.9440.7940.1650.3390.528

∗ Pearson's chi-squared test was used to determine genotype-phenotype association.

∗∗ Analysis of variance (ANOVA) test was used to determine genotype-phenotype association.

P value <0.05 was considered as significant.

Likewise, rs1045642 was the only ABCB1 SNP to be significantly associated with a clinical characteristic of BC, namely, age at breast cancer diagnosis (p value = 0.029) (Table 5). In contrast, rs2032582 was the only ABCB1 SNP to show significant association with a pathological characteristic of BC, namely, tumor size (p value = 0.03) (Table 5). The ABCG2 SNP rs2231142 was found to be significantly associated with axillary lymph node status (p value = 0.001) but not with any clinical characteristic (Table 5).
Table 5

Association between different ABCB1 and ABCG2 SNP genotypes and the clinicopathological characteristics of breast cancer (BC).

Clinical characteristics ABCB1 ABCG2
rs2032582 A vs C vs Trs1128503 AA vs AG vs GGrs1045642 CC vs CT vs TTrs2231142 GG vs GT
Body mass index ∗∗0.2980.3830.1800.164

Age at first pregnancy ∗∗0.2120.3260.8150.490

Age at BC diagnosis ∗∗0.9310.924 0.029 0.592

Allergy 0.3100.3310.1690.511

Age at menarche ∗∗0.5080.5250.1150.947

Breastfeeding status 0.7080.2910.6650.553

Age at menopause ∗∗0.7460.2580.6760.563

Family history 0.5850.6260.4690.481

Comorbidity 0.3500.3470.7510.341

Smoking 0.4620.365.3030.429

Pathological characteristics

Progesterone receptor status 0.3750.5550.2680.244

Estrogen receptor status 0.4700.4800.2990.312

HER2 0.7120.8860.8350.560

IHC profile0.1860.6450.1600.606

Tumor differentiation 0.4290.6320.5950.926

Axillary lymph nodes 0..3730.7180.8470.001

Tumor stage 0.7000.7050.7230.722

Histology classification 0.4880.4980.6020.648

Tumor size ∗∗0.0300.0320.5560.249

Lymph node involvement 0.0210..0560.4170.381

∗ Pearson's chi-squared test was used to determine genotype-phenotype association.

∗∗ Analysis of variance (ANOVA) test was used to determine genotype-phenotype association.

P value <0.05 was considered as significant.

3.4. Association between ABC Transporter SNPs and Immunohistochemistry (IHC) Profiles of Breast Cancer (BC)

Different combinations of the progesterone receptor, estrogen receptor, and Her2/neu expression molecular markers gives rise to three different immunohistochemistry profiles: Luminal A, Luminal B, and Triple Negative. These profiles and their correlation with the investigated SNPs are displayed in Tables 4 and 5. Only the ABCC1 SNP rs35626 was found to be significantly correlated with the different IHC profiles (p value = 0.013).

4. Discussion

In the present study, four ABC transporter genes were screened in female BC patients and healthy volunteers from Jordan. Three SNPs from each of the ABCC1, ABCC2, and ABCB1 genes and one SNP from the ABCG2 gene were investigated for their association with BC in patients of Jordanian-Arab descent. The ABCC1 (MRP1) gene has been previously reported as being a predictor of hematological toxicity in BC patients undergoing certain chemotherapy regimens [13]. It has also been found to be involved in MDR development in cases of neuroblastoma [14]. Moreover, ABCC1 expression was found to be increased in children with acute lymphoblastic leukemia, and ABCC1 gene induction resulted in worsened disease-free and overall survival rates [15, 16]. Our results show that none of the three investigated ABCC1 SNPs showed any significant association with the clinical and pathological characteristics of BC. However, we found that the ABCC1 SNP rs35626 was significantly associated with different immunohistochemistry (IHC) profiles in Jordanian-Arab patients. Similar to ABCC1, the ABCC2 gene is involved in decreased recurrence-free survival in BC patients receiving tamoxifen [17]. Nuclear expression of ABCC2 in BC cells was also found to be associated with worsened clinical outcome [18]. Our findings showed that the ABCC2 SNP rs2273697 was significantly associated with age at breast cancer diagnosis. Furthermore, rs2273697 was in correlation with estrogen receptor status for genotype association, patients were categorized according to the expression of estrogen receptor (positive versus negative) and tested with regard to their genotypes. However, in this study only gender was matched for the analysis. In addition, rs717620 was associated with breastfeeding status. Three ABCB1 SNPs rs1045642, rs1128503, and rs2032582 have been suggested to play a role in altered doxorubicin pharmacokinetics in Asian BC patients [19]. In the present study, all three aforementioned ABCB1 SNPs were significantly associated with BC in Jordanian Arabs. Moreover, the ABCB1 SNPs rs1045642 and rs2032582 were significantly associated with age at breast cancer diagnosis and tumor size, respectively. Overexpression of the ABCG2 gene was implicated in developing flavopiridol resistance in BC cells [20]. The homozygous genotype (CC) of the ABCG2 SNP rs2231142 of the ABCG2 gene resulted in significantly reduced intestinal transport activity compared to the wildtype (AA) [21]. In Kurdish BC patients, the A allele of the rs2231142 SNP may be a risk factor for BC progression, while the C allele was associated with poorer responses to anthracyclines and paclitaxel [22]. In contrast, the homozygous (CC) genotype of the ABCG2 SNP rs2231142 was significantly associated with longer progression-free survival in Han Chinese BC patients [23]. In the present study, the ABCG2 SNP rs2231142 was found to be significantly associated with axillary lymph node status in Jordanian BC patients. Conclusively, screening certain ABC transporter genes in BC patients and healthy volunteers from the Jordanian-Arab population revealed a number of interesting observations. Perhaps the most important finding was that the ABCB1 SNPs were the only variants to be significantly associated with BC in Jordanian Arabs.
  22 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  M Dean; A Rzhetsky; R Allikmets
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

Review 2.  The role of ABC transporters in drug resistance, metabolism and toxicity.

Authors:  Hristos Glavinas; Péter Krajcsi; Judit Cserepes; Balázs Sarkadi
Journal:  Curr Drug Deliv       Date:  2004-01       Impact factor: 2.565

3.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Authors:  R W Robey; W Y Medina-Pérez; K Nishiyama; T Lahusen; K Miyake; T Litman; A M Senderowicz; D D Ross; S E Bates
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

Review 4.  The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

Authors:  E Teodori; S Dei; C Martelli; S Scapecchi; F Gualtieri
Journal:  Curr Drug Targets       Date:  2006-07       Impact factor: 3.465

5.  Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.

Authors:  M Kourti; N Vavatsi; N Gombakis; V Sidi; G Tzimagiorgis; T Papageorgiou; D Koliouskas; F Athanassiadou
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 6.  ABC multidrug transporters: structure, function and role in chemoresistance.

Authors:  Frances J Sharom
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

7.  Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer.

Authors:  C Atalay; A Demirkazik; U Gunduz
Journal:  J Chemother       Date:  2008-12       Impact factor: 1.714

8.  Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.

Authors:  Suman Lal; Zee Wan Wong; Edwin Sandanaraj; Xiaoqiang Xiang; Peter Cher Siang Ang; Edmund J D Lee; Balram Chowbay
Journal:  Cancer Sci       Date:  2008-04       Impact factor: 6.716

9.  Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.

Authors:  Radka Vaclavikova; Silje H Nordgard; Grethe I G Alnaes; Miluse Hubackova; Eugen Kubala; Roman Kodet; Marcela Mrhalova; Jan Novotny; Ivan Gut; Vessela N Kristensen; Pavel Soucek
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

Review 10.  Role of the MRP1/ABCC1 multidrug transporter protein in cancer.

Authors:  Marcia Munoz; Michelle Henderson; Michelle Haber; Murray Norris
Journal:  IUBMB Life       Date:  2007-12       Impact factor: 3.885

View more
  6 in total

1.  Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Nancy M Hakooz; Mansour A Alghamdi; Rana B Dajani
Journal:  J Pers Med       Date:  2020-01-06

2.  Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.

Authors:  Eneida Turiján-Espinoza; Víctor Manuel Ruíz-Rodríguez; Edith Elena Uresti-Rivera; Ernesto Martínez-Leija; José de Jesús Zermeño-Nava; Arturo Guel-Pañola; Silvia Romano-Moreno; Juan Manuel Vargas-Morales; Diana Patricia Portales-Pérez
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-19       Impact factor: 3.333

Review 3.  Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer.

Authors:  Silvia Mara Baez Rodriguez; Georgiana-Adeline Staicu; Ani-Simona Sevastre; Carina Baloi; Vasile Ciubotaru; Anica Dricu; Ligia Gabriela Tataranu
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

4.  Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.

Authors:  Yu-Wen Huang; Chih-Yang Lin; Hsiao-Chi Tsai; Yi-Chin Fong; Chien-Kuo Han; Yuan-Li Huang; Wen-Tung Wu; Shih-Ping Cheng; Hao-Chiun Chang; Kuang-Wen Liao; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

5.  The Association of IL-1 and HRAS Gene Polymorphisms with Breast Cancer Susceptibility in a Jordanian Population of Arab Descent: A Genotype-Phenotype Study.

Authors:  Laith N Al-Eitan; Bashar H Al-Ahmad; Fouad A Almomani
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

6.  Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Mansour A Alghamdi; Rame H Khasawneh
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.